Oil protective composition

FIELD: chemistry.

SUBSTANCE: invention relates to application of composition, which contains Polygonum aviculare grass 20-25 wt %, cowberry leaves 13-17 wt %, Viburnum sargentii koehne fruits 5-9 wt %, fruits of dog-rose of different of Far-East species 20-25 wt %, Schisandra chinensis seeds 13-17 wt %, Fragaria orientalis leaves 5-9 wt % and corn stigmas 5-9 wt %, as means with oil protective activity in treatment of glomerulonephritis.

EFFECT: invention provides positive influence on basic indices of glomerulonephritis: promotes recovery of diuresis, reduction of proteinuria, reduction of azotemia, cryoglobulinemia and level of circulating immune complexes.

2 tbl


The invention relates to medicine, namely to pharmacology, pharmacognosy, namely, to the creation of vegetable origin that can be used as a nephroprotective funds for non-infectious chronic inflammation of the kidneys, namely glomerulonephritis.

The closest analogue prototype is a drug of plant origin, the composition of which per 100 g of the solution is the centaury grass 0.6 g, lovage medicinal roots 0.6 g, rosemary leaves 0.6 g, purified water 71,0 g, the ethanol content of 16.0 to 19.5% in volume ratio called Canephron N, the solution for the reception inside (instructions for use of the medicinal product for medical use. Bionorica. Canephron N. Reg. No P N014244/01).

The disadvantage of this herbal preparation are possible dyspepsia: nausea, vomiting, diarrhea, and the ethanol content limits the use of drugs in a number of diseases: alcoholism, liver disease, traumatic brain injury, brain disease, stomach ulcer and duodenal ulcer in the acute stage, the children's age. In addition, during drug treatment should drink plenty of fluids that are contraindicated in violation of the functions of the heart or kidney and high blood pressure�attachment.

The goal is to offer a composition of medicinal plants, which will not have an adverse action, as in the prototype, and will expand the base used medicinal plants.

The technical result is expressed nephroprotective effect in the treatment of glomerulonephritis.

The technical result is achieved in that the composition with a marked nephroprotective effect constitute from medicinal plants growing in the Far East under natural conditions in the following proportions in wt.%:

knotweed grass20-25
cowberry leaves13-17
Kalina of Sargent fruit5-9
rosehip miscellaneous
far Eastern species of the fruit20-25
schisandra chinensis seeds13-17
sheet strawberry East5-9
corn silk5-9

The study was performed on rats male line BD-9 Dark Agouty Massey-180 g On the model of experimental glomerulonephritis Hey-Mann studied specific nephroprotective activity of the composition.

Studies have shown improvement depurazione renal function, restoration of diuresis, reduction of erythrocyturia, displacement reaction of urine in the direction of increasing pH, reduction of swelling stroma, patellectomy capillaries, a decrease in tubular degeneration and leukocyte infiltration. There was a definite dose-response relationship nephroprotective activity of the composition and revealed good tolerance. The most active composition was acting as an infusion at a dose of 20 ml/kg for 28 days.

Based on the analysis of the obtained data it was found that the nephroprotective action of the composition is realized through reducing the severity of autoimmune processes in the glomeruli of the kidney Table.1, namely nephroprotective composition reduced immunological and biochemical parameters compared to control: the level of circulating immune complexes, cryoglobulins, creatinine, urea. Proteinemia also significantly decreased, indicating that improvement depurazione renal function when using this collection. Nephroprotective composition operates through the normalization of urodynamics Table.2.

Thus, nephroprotective composition positively influenced �and key indicators of glomerulonephritis: contributed to the restoration of diuresis, reduction of proteinuria, reduce azotemia, Criollo-bulinemia and the level of circulating immune complexes. In General, the studied composition is not inferior nephroprotective activity prototype Canephron, and on a number of indicators exceeded.

The advantages of the present composition:

- does not cause dyspeptic reactions from the gastrointestinal tract;

- does not require the use of large amounts of fluid;

- you can use a wider range of patients, including children;

- plants do not require special growing;

- plants are more active, as they grow in natural conditions, namely, Chinese Magnolia, rose Daur, echinated, wrinkled, Maksimovic, Ussuri, strawberry East, Kalina of Sargent are endemic in the Far East;

- the composition has a pleasant odor and taste;

- possible use in the treatment of any infectious chronic inflammatory diseases of the kidneys;

- does not contain ethyl alcohol.

Table 1
The nephroprotective effect of composition on the biochemical and immunological blood parameters in glomerulonephritis
Group/drugCEC, %KG, CL. OP×100Creatinine, mm/lUrea, mmol/lTotal protein, g/l
11th knots
Group intact-10-140.6 to 1.449-594,1-4,568 to 80
tion of rats
The group con28-36*3,9-4,9*98-114*7,3-7,7*51-59*
Control rats
Cameron N, 3.0 ml/kg25-33*2,6-3,8*85-99*6,2-6,6*53-59*
NC, 5.0 ml/kg 24-36*2,8-3,4*87 through 105*Between 6.5-7.3*47-65*
NC, 20.0 ml/kg24-30*3,8-4,2*87-101*6,4-7,0*53-61*
28 days
Group intact5-150,4-1,457-653,4-4,471-79
tion of rats
The group con43-51*5,5-6,7*167-181*8,7-9,1*29-35*
control rats
Camefrom N, 3.0 ml/kg16-28*/**2,7-3,1*7**9-111*/** 4,7-5,3**61-71**
NC, 5.0 ml/kg28-38*/**5,5-6,1*111-121*/**5,7-6,1**47-55**
HK, 20.0 ml/kg14-26*/**1,7-2,7*/**75-91*/**5,3-5,9**63-69**

where the CEC circulating immune complexes,

KG - cryoglobulins,

NC - nefroprotektornoy composition,

* - differences are significant but compared to intotime, p<0.05, and

** - significant differences compared with control, p<0,05.

Table 2
The influence of infusion nephroprotective songs in excretory renal function in glomerulonephritis
Group/drugDiuresis, % 01 load/4 hoursProtein, g/lErythrocytes, cells./µlPCE G/mg protein
The group con88-980,25-0,35 0-50,09-0,17
control rats
The group con26-38*2,41-3,09*370-470*2,06-2,28*
control rats
Canephron N, 3.0 ml/g69-77*/**0,52-0,72*/**12-38*/**0,93-1,25*/**
NC 5.0 ml/kg47-61*/**1,52-l,77*/**47-53*/**2,08-2,28*
NC 20.0 ml/kg64-74*/**0,72-0,84*/**15-35*/**1,56-1,74*/**

where PCE - pseudocholinesterase,

NC - nephroprotective composition,

* - ogliche significant compared to ipcache, p<0.05, and

** - significant differences compared with control, p<0,05.

The use of compositions containing th�CA bird grass 20-25 wt.%, cowberry leaves 13-17 wt.%, viburnum Sargenti the fruits of 5-9 wt.%, hips different far Eastern species of the fruits of 20-25 wt.%, schisandra chinensis seeds 13-17 wt.%, strawberry leaves East 5-9 wt.%, corn silk 5-9 wt.%, representing the infusion of these raw materials as a means with nephroprotective activity in the treatment of glomerulonephritis.


Same patents:

FIELD: medicine.

SUBSTANCE: group of inventions refers to medicine and concerns a diagnostic technique for renal disorders in dogs involving the stage of measuring an expression of biomarker group in a dog's biological sample, wherein the biomarkers represent clusterin (CLU), secreted frizzle-bound protein-2 (SFRP2); matrilin-2 (Matn2); lumican (LUM); decorin (DCN); alpha 1 (III) of collagen chain, variant 12 (COL3A1); retinol-binding protein 4 (rbp4); MMP-9; transferrin (TF); Apo-C-1 (ApoC1); and inhibin-beta A (INHBA). Besides, the group of inventions refers to a method of treating, relieving or delaying the renal disorders; a nucleic acid probe that is fragmented cRNA and hybridised with dog's gene; using the probe for preparing a kit applicable in accordance with the above method.

EFFECT: group of inventions provides diagnosing the renal disorders in dogs.

18 cl, 6 ex, 5 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to biotechnology. What is presented is a recovered human antibody or its antigen-binding fragment, which specifically binds to human angiopoietin-2 (hAng-2), but does not substantially binds to hAng-1 characterised by the presence of CDR variable heavy and light chain domains. What is described is a pharmaceutical composition on the basis of a therapeutically effective amount of the antibody. Disclosed are: variants of the recovered antibody or its antigen-binding fragment in producing drug preparation for treating a patient suffering various diseases including a tumour. Described are the versions of the methods of treating various diseases.

EFFECT: using this invention provides the antibody highly specific to human angiopoietin-2 (hAng-2) with an affinity constant of approximately 10-11, which does not substantially bind to hAng-1, that can find application in treating various diseases related to hAng-2 hyperactivity.

19 cl, 35 tbl, 3 dwg, 13 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to biotechnology and medicine. Administering into an individual a nucleic acid molecule, which is able to bind to MCP-1 and is an MCP-1 antagonist, wherein the nucleic acid molecule contains the nucleic acid sequence SEQ ID NO:37 in a combination with an immunosuppressive agent, for treating lupus nephritis enables reducing a dose of the immunosuppressive agent.

EFFECT: administering into the individual the nucleic acid molecule, wherein the nucleic acid molecule contains the nucleic acid sequence SEQ ID NO:37 has a therapeutic effect in treating pulmonary hypertension and chronic obstructive pulmonary disease.

30 cl, 54 dwg, 1 tbl, 12 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to substituted isoquinolines and isoquinolinones of formula (I) and to their stereoisomer and/or tautomer forms and/or pharmaceutically acceptable salts, wherein R1 is H, OH or NH2; R3 is H; R4 is H, halogen or (C1-C6)alkylene-R'; R5 is H, halogen, (C1-C6)alkyl; R7 is H, halogen, (C1-C6)alkyl, O-(C1-C6)alkyl; R8 is H; R6 is absent; or is one of (C1-C4)alkylene related to a cycloalkyl ring related to a cycloalkyl ring, wherein (C1-C4)alkylene forms a second bond to another carbon atom of the cycloalkyl ring to form a bicyclic ring system, R10 is H, phenyl, or pyridine, wherein phenyl is unsubstituted or substituted; R11 is H, (C1-C6)alkyl; or R11 and R12 together with the carbon atom to which they are attached form (C3)cycloalkyl; R12 is (C1-C6)alkyl, (C3-C8)cycloalkyl or phenyl; or R12 is H, provided r=2 and another R12 is other than H; or R11 and R12 together with the carbon atom to which they are attached form (C3)cycloalkyl; R13 and R14 are independently H, (C1-C6)alkyl, (C1-C6)alkylene-R', C(O)O-(C1-C6)alkyl, n is equal to 0; m is equal to 1 or 2; s is equal to 1 or 2; r is equal to 1 or 2; L is O, NH; R' is (C3-C8)cycloalkyl, (C6-C10)aryl; wherein in R11 and R12 residues, alkyl is unsubstituted or optionally substituted by one OCH3; wherein in R11 and R12 residues, alkyl is unsubstituted or optionally substituted by one or more halogens; wherein in R10 and R12 residues, (C6-C10)aryl is unsubstituted or optionally substituted by one or two groups optionally specified in halogen, CN, (C1-C6)alkyl, O-(C1-C6)alkyl, SO2-(C1-C6)alkyl, CF3 and OCF3. Also, the invention refers to using a compound of formula (I).

EFFECT: there are prepared new isoquinoline and isoquinolinone derivatives effective in treating and preventing the diseases related to Rho-kinase inhibition.

38 cl, 132 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to phenol derivatives of formula (1), wherein R1 represents C1-C6 alkyl group, C1-C6 alkynyl group, C1-C6 halogen alkyl group, C1-C6 alkyl sulphanyl group or a halogen atom, R2 represents a cyano group or a halogen atom, R3 represents a hydrogen atom, and X represents -S(=O)2. Besides, the invention refers to a drug preparation containing a compound of formula (I) as an active ingredient.

EFFECT: phenol derivatives of formula (1) characterised by the high urine concentration of the permanent compound, and possess the uricosuric action.

11 cl, 1 dwg, 2 tbl, 42 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to the pharmaceutical industry, in particular to a medication, possessing a nephroprotective action. The medication with the nephroprotective action, contains an extract of grass with roots and rhizomes of slender-leaf iris (Iris tenuifolia), stabilising agents and preservatives, taken in a certain ratio, where the extract is obtained by extraction of the grass with roots and rhizomes of slender-leaf iris (Iris tenuifolia) with a 30-70% water solution of polyol.

EFFECT: medication possesses an effective nephroprotective action.

3 cl, 3 dwg, 7 tbl, 14 ex.

FIELD: chemistry.

SUBSTANCE: invention relates to bi- and polycyclic substituted isoquinoline and isoquinolinones of formula (I), or to its stereoisomeric and/or tautomeric forms and/or to its pharmaceutically acceptable salts, where R1 represents OH; R3, R4, R5 and R8 represents H; R7 represents halogen or (C1-C6) alkyl; R6 represents one (C1-C4)alkylene, bound to a cycloalkyl ring, in which (C1-C4)alkylene forms the second bond with the other carbon atom of the cycloalkyl ring with the formation of a bicyclic ring system, where in the bicyclic ring system one carbon atom is substituted with a group, independently selected from O, S or SO2; and if m and s equal 2 or m equals 3 and s equals 1, R6 represents a group CH2-CH-(CH2)2, which via one group CH2 is bound to the cycloalkyl ring, and two other CH2 groups are bound to different carbon atoms of the cycloalkyl ring, and if m equals 3 and s equals 3, R6 represents two methylene groups, bound to different carbon atoms of the cycloalkyl ring, where the methylene groups or group CH2-CH-(CH2)2 are bound to the carbon atoms of the cycloalkyl ring and form an adamantane system of formula (XX) , where L can be bound to any secondary or tertiary carbon atom, or R6 together with R11 and an N atom form (C5) heterocycloalkyl, bound with the cycloalkyl residue in the form of a spirocyclic ring system, where the bicyclic ring system, or the adamantane system, or a ring system, containing (C5) heterocycloalkyl, represent non-substituted or optionally substituted with substituent R9; R9 represents (C1-C6)alkyl, (C2-C6)alkenyl, (C6)aryl or cyclopropyl R11 and R12 independently on each other represent H or (C1-C6)alkylene-(C6)aryl; n equals 0 or 1; m equals 2 or 3; s equals 1, 2 or 3; L represents O; its stereoisomeric and/or tautomeric forms and/or its pharmaceutically acceptable salts. The invention also relates to the application of a formula (I) compound.

EFFECT: novel bi- and polycyclic isoquinoline and isoquinolinone derivatives, useful as inhibitors of Rho-kinase, are obtained.

22 cl, 22 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to a novel derivative of N-acylanthranilic acid, represented by the following general formula 1, or to its pharmaceutically acceptable salt, in which R1, R2, R3, X1, X2, X3, X4 and A are determined in the invention formula.

EFFECT: invention relates to an inhibitor of collagen production, a medication for treating diseases, associated with the excessive production of collagen, containing N-acylanthranilic acid derivative Formula 1.

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to 6-substituted isoquinoline and isoquinolinone derivatives of formula or to its stereoisomer and/or tautomer forms and/or a pharmaceutically acceptable salt, wherein R1 represents H, OH or NH2; R3 represents H; R4 represents H, a halogen atom, CN or (C1-C6)alkylene-(C6-C10)aryl; R5 represents H, a halogen atom, (C1-C6)alkyl; R7 represents H, a halogen atom, (C1-C6)alkyl, O-(C1-C6)alkyl; R8 represents H; R9 and R6 are absent; R10 represents (C1-C6)alkyl, (C1-C8)heteroalkyl, (C3-C8)cycloalkyl, (C6)hetrocycloalkyl, (C1-C6)alkylene-(C3-C8)cycloalkyl, (C1-C6)alkylene-(C6-C10)aryl, (C1-C6)alkylene-(C6)heterocycloalkyl; R11 represents H; R12 represents (C1-C6)alkyl, (C3-C8)cycloalkyl, (C5)heteroaryl or (C6-C10)aryl; R13 and R14 independently represent H, (C1-C6)alkyl, (C1-C6)alkylene-R'; n is equal to 0; m is equal to 2 or 3; s is equal to 1 or 2; r is equal to 1; L represents O or NH; R' represents (C3-C8)cycloalkyl, (C6-C10)aryl; wherein in the rests, R10, R12-R14 alkyl or alkylene are unsubstituted or optionally substituted by one or more OCH3; wherein in the rests, R10, R12-R14 alkyl or alkylene are unsubstituted or optionally substituted by one or more halogen atoms; wherein (C1-C8)heteroaryl group means (C1-C8)alkyl groups, wherein at least one carbon atom is substituted by O;. (C6)heterocycloalkyl group means a monocyclic carbon ring system containing 6 ring atoms wherein one carbon atom can be substituted by 1 oxygen atom or 1 sulphur atom which can be optionally oxidated; (C5)heteroaryl means a monoring system wherein one or more carbon atoms can be substituted by 1 nitrogen atom or 1 sulphur atom or a combination of various heteroatoms. Also, the invention refers to using the compound of formula (I) and to a therapeutic agent based on the compound of formula (I).

EFFECT: there are prepared new compounds effective for treating and/or preventing diseases associated with Rho-kinase and/or mediated by Rho-kinase by phosphorylation of myosin light chain phosphatase, and the compositions containing these compounds.

32 cl, 111 ex

Phosphate adsorbent // 2527682

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to a pharmaceutical composition for phosphate adsorption in a body and/or from biological fluids when administered orally or externally, and to a biologically active food additive. The pharmaceutical composition and the biologically active food additive contains a physical mixture or a combination of powders, granules, crystals or chips of calcium, magnesium or iron salts in a certain mole relation of Ca2+, Mg2+ and Fe3+. The concentration of Ca+2 is 80 mg - 2,400 mg; the concentration of Mg+ is 49 mg - 729 mg and the concentration of Fe+3 is 112 mg - 1,676 mg in a daily dose.

EFFECT: invention provides effective binding of phosphate in a wide range of pH levels causing no overdosage of the consumed phosphate-binding compounds and enabling avoiding the related side effects.

20 cl, 10 dwg, 5 tbl, 16 ex

FIELD: medicine.

SUBSTANCE: integrated therapy additionally involves administering thin-walled Capsicum annuum powder of the type paprika in a dose of 30 g with the specified selenium contents of 1 mg/kg and a capsule of alpha-tocopherol acetate in a dose of 100 mg manufactured by Lyumi, LLC (Ekaterinburg) orally during meals 3 times a day. The length of the treatment is 20 days.

EFFECT: invention enables reducing the time of the treatment, increasing its efficacy, and prolonging remission.

1 tbl, 2 dwg, 2 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine. Described is a wet product from a non-woven material, soaked with a substance for personal hygiene, which is applied in household or for local processing for medicinal purposes. The non-woven material represents a bonded fibrous cloth, possessing hydrophilic properties, or a fibrous cloth, to which hydrophilic properties have been applied by processing with moisturising additives.

EFFECT: wet product possesses the high absorbing property and increased ability of releasing a substance, possessing the absorbing ability, and its transfer onto the surface.

21 cl, 3 tbl

FIELD: medicine.

SUBSTANCE: invention refers to dentistry, namely represents an encapsulated oral care composition and an oral care device. According to the invention, the composition contains: (a) a gelatine capsule; and (b) an oral care composition inside the capsule and containing: (i) a hydrophilic active ingredient, (ii) a hydrophobic structuring ingredient, and (iii) an oil carrier. The hydrophilic active ingredient preferentially represents cetylpyridinium chloride. The hydrophobic structuring ingredient preferentially represents gelated mineral oil.

EFFECT: developing the composition according to the invention solves the problem of cetylpyridinium chloride migration and fish-eye capsule defect.

9 cl, 1 ex, 1 tbl

FIELD: chemistry.

SUBSTANCE: claimed invention relates to cosmetic field, namely represents method of colouring or lightening of keratin fibres, which includes stage of mixing without preparation at the moment of application of two compositions (A) and (B) and application of said mixture on said fibres; with said mixture including, at least, 25% of fatty substances relative to the total weight of composition, obtained in mixing two compositions (A)+(B).

EFFECT: method by invention makes it possible to produce intensive and uniform colouring of keratin fibres, with method simultaneously being easy to realise, because mixture in form of oil-reach emulsion does not flow down, but remains on application place, as well as makes it possible to lighten keratin fibres.

19 cl, 3 tbl, 1 ex

Shower gel // 2555358

FIELD: cosmetology.

SUBSTANCE: shower gel comprises lauryl glucoside, sodium carboxylate and lauryl glucoside, coco glucoside, cocon amidopropylbetaine, guar-hydroxypropyltrionium chloride, coco glucoside and glyceryl oleate, ethyl alcohol, a fragrance component, sanguinitrine derived from small-fruited plumepoppy, citric acid and water. The components of the gel are in a certain ratio in wt %.

EFFECT: invention provides high washing and foam-generating capacity with soft action which does not disturb the lipid layer of the skin and has a disinfecting action, without destroying own microflora of human skin.

3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions relates to liposomal compositions for application in cosmetic industry, including i) from 0.001 to 1 wt % of cyclo-(Arg-Gly-Asp-DPhe-Acha) and/or its salt or solvate, ii) from 0.01 to 20 wt % of one or more lipids; iii) from 60 to 99.99 wt % of one or more physiologically acceptable solvents, as well as to method of their obtaining and application for care and preservation of general condition of skin or hare, for prevention or reduction of wrinkles.

EFFECT: claimed compositions demonstrate favourable properties: improved effectiveness, higher stability, reduced immunogenic reactions in comparison with known properties.

18 cl, 3 dwg, 29 tbl, 18 ex

FIELD: chemistry.

SUBSTANCE: present invention relates to cosmetology and hygiene and provides a foaming detergent composition which contains: a) surfactants consisting of decyl glucoside and coco glucoside, where the decyl glucoside is present in an amount by weight which is 1.8 to 2.2 times the weight of coco glucoside, and b) water, where the amount of decyl glucoside is 10 to 30 wt % of the composition, wherein the composition is free of anionic surfactants.

EFFECT: invention enables to produce a detergent composition having foaming properties in the absence of an anionic surfactant that are equally effective as with a composition with an anionic surfactant.

23 cl, 6 ex

FIELD: cosmetology.

SUBSTANCE: invention is the biological means for cleaning and restoration of skin, comprising pancreatic tissue of pigs or birds, 70% ethyl alcohol, fragrance component, and Ringer's solution, at that the components in the means are in a certain ratio, in wt %.

EFFECT: acceleration of the process of skin regeneration, expanding of range of means having cleaning and skin restoring action.

3 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: implementing the presented method involves mixing gel Hyaludent 1 ml on a slide with Betaleukin 0.0005 ml dissolved in water for injections 1 ml; the produced content is applied with a single application syringe on a desalivated treated area of the involved periodontal tissues and left until completely absorbed for 1-3 minutes; the involved area is exposed to laser light generated by the laser semiconductor dental therapeutic apparatus Optodan with a periodontal tip in the mode II, with the exposure length for 3-5 minutes; the therapeutic course is 8 days daily.

EFFECT: using the method enables achieving the fast regeneration length, ensuring the intact periodontal state in the most patients.

4 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention aims at treating drug-induced dry eye syndrome (DI-DES). Treating DI-DES implies taking the past medical history, measuring tear production and eye xerosis values reduced and increased respectively in relation to the norm. Unpreserved ocular hypotensive medications are prescribed in the patient. Unpreserved artificial tears are also applied. The lachrymal fluid is analysed by a multicytokine technique. If the analysis shows increased concentrations of proinflammatory cytokines - interleukin-6, interleukin-8, interleukin-12, Th-1 - interleukin-2, interferon-gamma, and Th-2 - interleukin-4, by min 30% in relation to the patient's age norm, a chronic immune ocular inflammation is detected. That requires transpalpebral Blepharogel-1 phonophoresis and 1% hydrocortisone ointment phonophoresis on the sub-mastoidal region from both sides; the therapeutic course is 8-10 daily procedures.

EFFECT: optimal conditions for diagnosing and reasoned differentiated therapy of DI-DES that enables prescribing the pathogenetically reasoned therapy in due time and increasing the efficacy of the therapeutic exposure.

1 tbl, 2 ex

FIELD: medicine, oncology, amino acids.

SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.

EFFECT: valuable medicinal antitumor properties of preparation.

8 cl, 4 tbl, 2 dwg, 4 ex